Adverse Event reporting information can be found in footer
Request a Meeting
(desmopressin [as acetate] oral lyophilisate)
Primary nocturnal enuresis (PNE) is a distressing condition that can have a significant impact on a young person’s behaviour and emotional and social well-being1,2. DesmoMelt is well accepted by children of various ages and facilitates early intervention3, providing an effective and convenient solution to primary nocturnal enuresis and helping children and families return to a normal life.
DesmoMelt is licensed for the treatment of PNE in children and adults aged 5 to 654 and is the preferred paediatric formulation in children aged 5–11 years3. DesmoMelt is associated with a significant improvement in diuresis rate and numerically higher compliance compared with the tablet3,5.Learn More
Primary nocturnal enuresis (PNE) is a distressing condition that can have a significant impact on a young person’s behaviour and emotional and social well-being.1,2.
DesmoMelt is a sublingual oral lyophilisate formulation of desmopressin, licensed for the treatment of primary nocturnal enuresis (PNE) in children and adults aged 5 to 65.4Learn More
Desmopressin is recommended by NICE as an initial treatment strategy for bedwetting in children from the age of 5 years old, under certain circumstances6.Learn More
Due to its formulation, DesmoMelt is associated with numerically a higher compliance level vs. the tablet and retains similar levels of efficacy and safety at lower dosing levels3.
Watch this short clip which shows how quickly the sublingual formulation gets to work versus the tablet formulation.
Job Code: UK-MN-2200029 - Date of preparation: March 2023